Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the
leading cause of serious illness across the globe. It is the main cause of
pneumonia, sinusitis, blood infections, meningitis, and middle ear infections
(otitis media). Pneumococcal disease affects children and the elderly, and it
is one of the leading infectious diseases worldwide. It kills almost 1.6
million people (including more than 800,000 children under the age five years)
every year. Pneumococcal disease can be prevented by vaccination. Vaccination
involves the introduction of dead or weakened antigen into the human body,
which in turn produces lymphocytes to counter the infection and any future
invasions by that antigen.
Analysts forecast the Global Pneumococcal
Vaccines market to grow at a CAGR
of 4.90 percent over the period 2013-2018.
Covered in this
Report
This report covers the present scenario and the growth prospects of the
Global Pneumococcal Vaccines market for the period 2014-2018. To calculate the
market size, the report considers the revenue generated through the sales of
various vaccines administered to actively immunize pneumococcal disease caused
by different serogroups of Streptococcus pneumonia.
Global Pneumococcal Vaccines Market 2014-2018, has been prepared based on
an in-depth market analysis with inputs from industry experts. The report
covers the Americas, and the APAC and EMEA regions; it also covers the Global
Pneumococcal Vaccines market landscape and its growth prospects in the coming
years. The report includes a discussion of the key vendors operating in this
market.
Single User License of the Report is Available
at USD 2500, Buy the Report @ http://www.sandlerresearch.org/purchase?rname=23070 .
